Lasa Supergenerics

Lasa Supergenerics FCF Yield

The Free Cash Flow Yield of Lasa Supergenerics (LASA.NS) as of Nov 3, 2026 is -37.45 %. In the previous year, Free Cash Flow Yield was -19.32 % — a change of 93.81% (lower).

FCF Yield

-37.45 %

YoY

93.81%

Last updated:

Free Cash Flow Yield of Lasa Supergenerics is 2026 -37.45 % . Free Cash Flow Yield of Lasa Supergenerics was 2025 -19.32 % . It decreases by 93.81% lower compared to the previous year.

The Lasa Supergenerics FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
68.07 INR
Jan 1, 2020
30.16 INR
Jan 1, 2021
80.59 INR
Jan 1, 2022
-0.13 INR
Jan 1, 2023
-40.15 INR
Jan 1, 2024
-0.43 INR
Jan 1, 2025
-19.32 INR
Jan 1, 2026
-37.45 INR
The Lasa Supergenerics FCF Yield history
YEARFCF YieldYoY
-37.45 %+93.81%
-19.32 %+4,434.37%
-0.43 %-98.94%
-40.15 %+31,241.30%
-0.13 %-100.16%
80.59 %+167.20%
30.16 %-55.69%
68.07 %-556.37%
-14.91 %+37.00%
-10.89 %+1,240.23%
-0.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lasa Supergenerics Stock analysis

What does Lasa Supergenerics do? Lasa Supergenerics Ltd manufactures veterinary preparations including API products such as Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others. The company also produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Its manufacturing facility in Mahad and Chiplun, Maharashtra, supports the production of these specialized veterinary and pharmaceutical products. The company's primary customers are likely veterinary pharmaceutical manufacturers and animal health suppliers who require API products, feed additives, and therapeutic reagents. These segments include the veterinary pharmaceutical industry and animal feed production sectors, which rely on Lasa Supergenerics' specialized chemical formulations for their own product lines. The firm's focus on catalyst chemistry and anthelmintic/veterinary API products positions it within the niche market of veterinary pharmaceutical manufacturing. Lasa Supergenerics generates revenue through the sale of its API products, animal feed ingredients, and therapeutic reagents to veterinary and pharmaceutical companies. The company's product portfolio targets the veterinary pharmaceutical sector, where demand for anthelmintic and other API-based solutions is significant. By specializing in catalyst chemistry and producing high-demand veterinary API products, the company serves a specific market segment with tailored chemical solutions. Lasa Supergenerics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lasa Supergenerics stock

Free Cash Flow Yield of Lasa Supergenerics is -37.45 % in 2026.

Free Cash Flow Yield of Lasa Supergenerics changed from -19.32 % to -37.45 %, representing a 93.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Lasa Supergenerics since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Lasa Supergenerics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lasa Supergenerics

All Key Metrics — Lasa Supergenerics